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Abstract
Background: In the treatment of multiple sclerosis, a change of therapy is considered after treatment failure or
adverse events. Although disease modifying drugs’ (DMD) efficacy and side effects have been fully analysed in
clinical trials, the effects of previous therapy use are less well studied. We aimed to study medication persistence
with glatiramer acetate in treatment-naive patients and in patients previously treated with interferon.
Methods: A retrospective study of relapsing-remitting multiple sclerosis patients treated with glatiramer acetate in
an MS Unit of a Spanish University Hospital (January 2004 – September 2013). Treatment time on glatiramer acetate
was studied. Reasons for treatment discontinuation were considered as follows: lack of efficacy, serious adverse
event, injection-related side effect, pregnancy and lost to follow-up. Use of prior DMD was registered and analysed.
Homogeneity of groups was analysed using Fisher's and Mann-Whitney’s tests. The Kaplan Meier method and Cox
regression model were used to estimate time to and risk of treatment discontinuation.
Results: In total, 155 relapsing-remitting multiple sclerosis patients were treated with glatiramer acetate: 100 treatment-
naive patients and 55 treated previously with interferon. At the end of the study, 76 patients (49.0 %) continued on
glatiramer acetate (with an average treatment time (ATT) of 50.4 months, s.d.32.8) and 50 patients (32.3 %) had switched
therapy: 27 patients (17.4 %) for inefficacy (ATT 29.2 months, s.d.17.5), 20 patients (12.9 %) for injection site reactions (ATT
16.5 months, s.d.20.3) and 3 patients (1.9 %) after serious adverse events (ATT 15.7 months, s.d.15.1). ATT in our cohort
was 39 months (s.d.30.0), median follow-up 34 months. Six months after glatiramer acetate initiation, probability
of persisting on GA was 91.4 %, 82.5 % after 12 months and 72.5 % after 2 years. The risk of glatiramer acetate
treatment discontinuation was 2.8 [1.7 – 4.8] times greater for treatment-naive patients than for patients treated
previously with interferon and this was hardly modified after adjusting for sex and age.
Conclusions: Glatiramer acetate was safe and useful with low rates of serious adverse events and low rates of
break-through disease. Injection intolerance proved a major limitation to glatiramer acetate use. Patients who
had been previously treated with interferons presented a lower probability of glatiramer acetate discontinuation
than treatment-naive patients.
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Background
When treating multiple sclerosis (MS) patients, the main
goal is to slow disease progression and improve health-
related quality of life [1]. Selecting an optimal individual-
ized treatment for MS patients is becoming progressively
more complicated as treatment options and their side
effects increase [2, 3].
Both interferons (IFNs) and glatiramer acetate (GA)
are injectable disease modifying drugs (DMDs) approved
and used as first-line therapies in MS. If disease activity
is still observed despite treatment or if adverse events
occur, a therapy switch is considered. Some studies con-
clude that switching between injectable DMDs, mainly
from IFNs to GA, can result in a substantial relapse rate re-
duction, both for patients switched for treatment failure as
well as for those who are switched for other reasons [4–8].
Although DMD efficacy and side effects have been
fully studied in clinical trials, the effects of previous
therapy use are less well known. Analysing experience
gathered from ‘real-world’ clinical practice could help
make rational individualised treatment decisions. Treat-
ment persistence with GA when used after treatment fail-
ure with IFNs is not well characterized. The aim of this
pilot exploratory study was to describe GA use and
treatment persistence, measured as time to GA treat-
ment discontinuation, in a group of Relapsing Remitting
MS (RRMS) treatment-naive patients and in a group of




An independent, retrospective observational study was con-
ducted at an MS Unit of a tertiary University Hospital.
Clinical records were used to identify patients who had
been prescribed glatiramer acetate (GA) between January
1st 2004 and October 1st 2013. Clinical diagnosis, prior
DMD treatment, dates of GA treatment initiation and end,
as well as reasons for GA treatment discontinuation, were
studied. Patients were included according to their clinical
history in one of the following groups: treatment-naive pa-
tients and patients treated previously with IFN. All RRMS
patients who had been exposed to IFN before initiating
treatment with GA were included.
Treatment failure was defined as reasons given by the
treating neurologist for GA discontinuation. The follow-
ing reasons were considered: lack of efficacy (including re-
lapses, progression of disability or magnetic resonance
imaging (MRI) activity), occurrence of serious adverse event
(SAE), injection site reactions, pregnancy or pregnancy
planning at study end-point and loss to follow-up. Time to
treatment discontinuation was studied. End of observation
period was October 1st 2013. Treatment time for each indi-
vidual patient was calculated in months as the time lapse
between GA treatment initiation and the last documented
injection. Average treatment times (ATT) were calculated
for each group.
Patients
The study was conducted at the Neurology Department of
La Paz University Hospital in Madrid. In total 155 patients
met inclusion criteria: age ≥18 years, RRMS diagnosis
according to 2010 revised McDonald criteria [9] and treat-
ment with GA between January 1st 2004 - October 1st
2013. Patients were excluded if another diagnosis different
from MS was given on follow-up. Patients were then ex-
cluded from statistical analysis if data regarding GA
initiation and end dates was missing.
Throughout the study period DMD initiation and
change were performed at the discretion of the MS Unit
medical team following usual clinical practice [3, 10, 11].
A lack of efficacy or suboptimal response to GA was
considered the reason for a treatment change based on
the patient’s clinical history, considering the occurrence
of relapses (≥2 relapses or 1 severe relapse), accrual of
disability or disease activity on follow-up MRI (presence
of gadolinium-enhancing lesions or increased T2-lesion
load, including both new and enlarging T2-lesions).
Clinical, including EDSS scores, DMD initiation and
end dates, and MRI data were collected and stored in
an electronic database. All patients underwent regular
follow-up consisting of six-monthly neurological as-
sessments and laboratory testing including liver and
thyroid gland function. After therapy approval by the
health authorities, all patients received training sessions on
self-injectable DMD administration by a nurse who specia-
lised in the care of MS patients. In the training sessions
realistic expectations were established, side effects were an-
ticipated, as well as their management, and administration
technique was taught. After training, patients self-injected
the DMD at home. If they had questions, patients could
use a telephone help-line staffed by nurses and neurologists.
Unscheduled visits were performed for the assessment and
treatment of side effects, relapses or any other clinically
relevant condition. This study is a retrospective analysis of
our MS clinical data, and has been conducted using data
that was anonymized for analysis so specific written in-
formed consent was not obtained from patients. This
study has been performed according to the regulations
of the Ethics Committee of La Paz University Hospital.
Data analysis
Statistical analysis was performed using SAS 93 (SAS
Institute, Cary, NC, USA). Quantitative data are de-
scribed using the mean ± standard deviation (± s.d.),
median and range. Qualitative data are described using
absolute frequencies and percentages. The homogeneity of
the groups was analysed using Fisher's exact test for
Fernández-Fournier et al. BMC Neurology  (2015) 15:141 Page 2 of 8
categorical data and Mann-Whitney’s test for quantita-
tive data. Treatment time on GA was studied. The
Kaplan Meier method was used to estimate time to
treatment discontinuation. Risk of treatment discon-
tinuation was estimated using a Cox regression model,
with and without adjusting for sex and age at the time
of GA initiation. The independent variable of this
study was time to GA treatment discontinuation, de-
fined as the time lapse between treatment initiation
and treatment discontinuation in months. Patients
who were still treated with GA on October 1st 2013
and those lost to follow up on treatment with GA have
been considered censored values as per survival ana-
lysis. Estimated Hazard ratios with their 95 % confi-
dence intervals are provided.
Results
Between January 1st 2004 and October 1st 2013, 155
RRMS patients (68.3 % females) who were treatment-
naive (100 patients) or had been previously treated
with IFNs (55 patients) were prescribed GA at the
Neuroimmunology and MS Unit of La Paz University
Hospital. Ages at GA treatment initiation ranged from
17 to 60 years of age, average 37(± 9) and were similar
for both treatment groups (treatment-naive patients
and patients treated previously with IFN). There was a
tendency for a greater proportion of females in the
treatment-naive group (73 % vs. 58.1 %, P = 0.073). Median
EDSS at GA prescription was similar for both groups
(Table 1).
At the end of the study (Fig. 1), from the 155 patients,
76 patients (49.0 %) were still being treated with GA.
Prescription had been withdrawn in 50 cases (32.3 %), 3
patients (1.9 %) had temporarily stopped GA for pregnancy
planning and 26 patients (16.8 %) had been lost to follow-
up (Fig. 2). From the 50 patients who stopped GA, all
patients with previous IFN exposure escalated therapy to
second line drugs, while those in the treatment-naive group
followed a variety of pathways, including switching to
second-line drugs (60.4 % patients), but also to IFN
(29.2 %) and immunosuppressive drugs (4.2 %), as well as
stopping treatment altogether following patients’ demands
(4.2 %) or conversion to secondary progressive MS (2.1 %).
In our cohort, reasons for stopping GA treatment
were: (a) lack of efficacy, including relapses (22 patients,
14.2 %), disability accrual (3 patients, 1.9 %) or evidence
of disease activity on follow-up MRI (2 patients, 1.3 %);
(b) injection intolerance (20 patients, 12.9 %): mainly
injection pain and mild-moderate skin reactions such as
redness or itching; (c) SAEs (3 patients, 1.9 %): injection
associated unremitting chest pain, allergic reactions or
severe local reactions such as marked lipoatrophy.
Amongst patients who discontinued GA due to injection
intolerance, most (n = 19 patients, 95 %) belonged to the
treatment-naive group.
Overall, patients in our cohort were treated with GA
an average of 39 months (s.d 30.0). Median follow-up
was 34 months. Six months after GA treatment initi-
ation, probability of continuing on GA was 91.4 %
(88.6 % for treatment-naive patients and 96.3 % for
patients previously treated with IFN). Twelve months
after treatment initiation, probability of continuing on
GA was 82.5 % (76.8 % for treatment-naive patients
and 92.5 % for patients previously treated with IFN).
Two years after treatment initiation, probability of
continuing on GA was 72.5 % (62.3 % for treatment-
naive patients and 90.6 % for patients previously
treated with IFN). Treatment-naive patients were
found to be significantly more prone to discontinue
GA than those with previous exposure to IFNs (Fig. 3).
The risk of GA discontinuation was 2.8 [C.I. 95 %: 1.7
– 4.8] times greater for treatment-naive patients and
this was hardly modified after adjusting for sex and age
(3.0 [C.I. 95 %: 1.8 – 5.2]).
Table 1 Characteristics of patients treated with glatiramer acetate (GA), January 2004 – October 2013
Total patients (n = 155) Treatment-naive (n = 100) Previous treatment with interferon (n = 55) P
Age: range, y 17 – 60 17 – 56 24 – 60 p = 0.3
Mean (± s.d.) 37 (± 9) 37 (± 9) 38 (± 8)
Female sex, n (%) 106 (68.3) 73 (73.0) 32 (58.1) p = 0.07
Geographical origin
South Europe (Spain), n (%) 145 (93.5) 94 (94.0) 51 (92.7)
Eastern Europe, n (%) 2 (2.0) 1 (1.8)
North Africa, n (%) 2 (2.0) 1 (1.8)
South America, n (%) 2 (2.0) 2 (3,6)
Time to treatmenta: Mean (± s.d.), y 5.2 (± 5.9) 2.7 (±5.5) 6.7 (± 5.7) p < 0.001
EDSS at GA initiation (median [IQR]) 1.5 [1–3]b 2 [1–3]b p = 0.2
y years, s.d standard deviation, GA Glatiramer Acetate, IQR Interquartile Range
aTime to treatment = Average time-lapse from diagnosis to GA treatment initiation
bEDSS at GA initiation data availability of 55 %
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Regarding time spent on GA, ATT for patients who
persisted on GA at the end of the study was 50.4 months
(s.d. 32.8). Patients who discontinued GA for lack of ef-
ficacy had an ATT of 29.2 months (s.d. 17.5), amongst
patients discontinuing for SAEs, ATT was15.7 months
(s.d. 15.1) and for injection site reactions ATT was
16.5 months (s.d. 20.3). Amongst patients lost to follow-
up, ATT was 37.8 months (s.d. 26.3). ATT for patients
discontinuing GA for pregnancy planning was 29.7 months
(s.d. 6.0) (Fig. 4).
Discussion
We present an independent, observational study analysing
treatment persistence on glatiramer acetate (GA) in an MS
Unit of a Spanish tertiary University Hospital. Little is
known on how the use of previous DMDs affects treatment
outcome. This is the second published study that aims to
describe differences in treatment persistence with GA in
treatment-naive patients with respect to patients previously
treated with IFNs, and the first to do so in Europe.
Subcutaneous GA is a well-established treatment for
RRMS. Although GA’s exact mechanism of action remains
to be fully elucidated, key roles seem to be modulation of
inflammatory response and neuroprotective effects [12].
Clinical trials and follow-up studies have shown that GA re-
duces clinical and radiological disease activity, proves more
effective than placebo and shows at least similar efficacy to
subcutaneous IFN β-1a and IFN β-1b [12–18]. In the litera-
ture, GA is described to be effective both in treatment-
naive patients and in those switching from a previous
DMD because of lack of efficacy or side effects [19].
The current paradigm is to start RRMS treatment
with injectable DMDs as a first-line therapy and then
advance into the therapeutic pyramid until the disease
is effectively controlled. However, first-line treatment
failure with IFNs may be due to the existence of neu-
tralizing antibodies [12], poor tolerance or occurrence
of adverse events, and may not reflect the need to es-
calate to second-line therapies such as Fingolimod or
Natalizumab. Second-line drugs offer potentially greater ef-
ficacy, but are associated with an increased level of risk [3,
Fig. 1 Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with glatiramer acetate (GA), January 2004 – October 2013. Flow chart showing
prescription of glatiramer acetate (GA) for Relapsing Remitting Multiple Sclerosis (RRMS) patients at the Neuroimmunology and MS Unit of La Paz
University Hospital, Madrid, Spain, from January 2004 to October 2013. Patients lost to follow-up, those excluded from statistical analysis and reasons
for stopping GA treatment are indicated
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20], also costs sometimes need to be taken into account
when evaluating treatment options. Thus, changes between
first-line agents may be, in some cases, a suitable option.
In contrast to the situation in clinical trials, switching
between DMDs is common in daily practice. Studying
treatment use and response in ‘real-world’ clinical prac-
tice is relevant for the future care of RRMS. It is import-
ant to address questions not answered by clinical trials
regarding not only efficacy, but also tolerability and
treatment persistence [21]. Treatment persistence varies
Fig. 2 Proportion of patients in each treatment persistence group. Graph showing proportion of patients according to different glatiramer acetate
(GA) treatment persistence groups at the Neuroimmunology and MS Unit of La Paz University Hospital on October 1st 2013
Fig. 3 Treatment persistence on glatiramer acetate (GA) of treatment-naive patients and of patients treated previously with interferon (IFN). Kaplan-
Meier survival curves showing treatment persistence on glatiramer acetate (GA) of treatment-naive patients and of patients previously treated with
another disease modifying therapy (interferon)
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with country of residence [22]. Jokubaitis et al. compared
treatment persistence on GA and IFN in Australian pa-
tients and report that, in their cohort, patients receiving
IFNβ-1a as a first DMD persisted longer on treatment than
those treated with GA as a first DMD [22]. Similarly,
Kleinman et al. found lower discontinuation rates on IFN β
than on GA in the US [23]. On the other hand, data from
the REGARD clinical trial do not show significant differ-
ences in treatment persistence between IFNβ-1a and GA
[24]. In the Australian cohort, higher EDSS and younger
age at DMD initiation were predictive of treatment discon-
tinuation, however in our cohort, adjusting for age hardly
modified the relative risk of GA discontinuation. Another
study on DMD use reported female sex as a predictive
factor of treatment discontinuation [25], but this was
not reproduced in the Australian study or in our cohort.
Missing data do not allow us to conclude if EDSS is pre-
dictive of treatment discontinuation in our cohort.
With respect to efficacy, GA was useful in our ‘real
world’ setting, with only 17.4 % of patients presenting
breakthrough disease (relapses, progression of disabil-
ity or MRI activity), which is lower than that of clinical
trials and on the low end of reported breakthrough dis-
ease for clinical practice, which is of 18 – 30 % in
5 years for first-line DMDs [19]. This difference might
be explained by clinical trials’ selective inclusion cri-
teria that tend to include only highly active patients
with a greater probability of break-through disease
than that of “the average MS patient”. It may also re-
sult from underestimating real breakthrough activity,
as patients who might have remained on GA despite
disease activity are not included.
Regarding safety and tolerability, subcutaneous GA was
generally well tolerated in clinical trials and extension stud-
ies, the most commonly reported adverse event being
injection site reactions and mild vasodilation [12]
(http://www.copaxone.com/about-copaxone/copaxone-
safety-and-effectiveness, cited 2014 Mar 14). Our re-
sults agree with clinical trials regarding treatment
safety, only 1.9 % patients developed relevant medical
side-effects (injection associated unremitting chest
pain, allergic reactions or severe local reactions such
as marked lipoatrophy). However, our data show a
relatively high treatment discontinuation rate (12.9 %)
due to injection intolerance (mainly injection pain
and mild-moderate skin reactions, including redness
and itching), mostly amongst treatment-naive patients,
and this was independent of gender. Along these
lines, previous studies indicate that the lack of treat-
ment tolerance is a major reason for DMD discon-
tinuation [22, 26, 27].
The overall risk of GA treatment discontinuation in
our cohort was almost 3 times greater for treatment-
naive patients than for patients treated previously with
IFN. Similarly, Jokubaitis et al. report lower treatment
persistence on GA than on IFN only amongst treatment-
naive patients and not when these drugs were used as
second therapies [22]. We believe this might be influenced
by non-naive patients being used to self-injections.
Patients who discontinue treatment with IFNs may do
so because of side-effects or disease activity. With regard
to risk-benefit ratios, MS disease activity of some
patients may not justify assuming the potential risks of
second-line drugs. This study argues in favour of
Fig. 4 Average treatment-time with glatiramer acetate (GA) according to patient’s treatment persistence group. Graph showing average treatment-
time (ATT) in months (±standard deviation) with glatiramer acetate (GA) at the Neuroimmunology and MS Unit of La Paz University Hospital between
January 2004 and October 2013, according to patient’s GA treatment persistence category
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incorporating GA in the MS therapeutic algorithm not only
as an initial agent but as a second therapy for certain pa-
tients who discontinue treatment with IFNs. Further inves-
tigation regarding reasons for treatment discontinuation
and comparisons between treatment-naive patients and
switchers is required.
Limitations to our study include the retrospective de-
sign that limits study variables. The prevalence of IFN
neutralizing antibodies was not consistently checked,
treatment compliance was not well recorded and no
questionnaire addressing patients’ perception of treat-
ment was administered. Other limitations of this study
are cohort size and loss to follow-up, with 26 patients
(16.8 %) lost to follow-up on treatment with GA, how-
ever this seems reasonable taking into account the
10 year time-span of the study. This pilot study was de-
signed as an exploratory study so we were not able to
conduct certain sub-analysis. We were not able to elim-
inate potential bias by adjusting for disability which can
influence treatment persistence [22, 25]. However, despite
the limited sample size, significant results are obtained in
treatment persistence between treatment-naive patients
and patients treated previously with IFN. Regarding the
clinical applicability of these results, the time frame must
be taken into account as it may influence treatment persist-
ence. In our cohort, patients who discontinued GA for lack
of treatment efficacy were on GA for over two years
(29.2 months (±17.5)). Patients underwent regular follow-
up visits at least twice per year, so GA might be seen a use-
ful initial treatment even if long-term response is subopti-
mal. However, patients might have remained on GA
waiting for the arrival of new therapies. Between 2004 and
2013 progress in the treatment of MS was remarkable, with
new second-line drugs being licensed. At the same time,
MRI criteria for early identification of non-responders were
developed and progressively incorporated into clinical prac-
tice. With regard to the future, the situation is one of an in-
creasing complexity, as new oral drugs, available as first-
line therapies, arrive [20, 28].
A recent review comparing comparing the efficacy of
IFN with that of GA in RRMS concludes that, even if
safety and efficacy parameters of both drugs are similar,
patient needs such as different levels of tolerability need
to be addressed and taken into account for treatment
choice [29]. A prospective study with questionnaires spe-
cifically addressing subjective perception of treatments
as well as treatment adherence, in both treatment-naive
patients and switchers, might shed light on the differen-
tial treatment persistence.
Conclusions
In summary, GA was safe and useful with low rates of
serious adverse events, similarly to previously published
data, and low rates of break-through disease. Injection
intolerance proved a major limitation to GA use, mostly
amongst treatment-naive patients. We conclude that
prior DMD use seems to influence persistence on GA;
patients with previous exposure to IFN presented a sig-
nificantly lower probability of GA treatment discontinu-
ation than treatment-naive patients.
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